2223 related articles for article (PubMed ID: 25417114)
1. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
2. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma.
Costa V; Esposito R; Ziviello C; Sepe R; Bim LV; Cacciola NA; Decaussin-Petrucci M; Pallante P; Fusco A; Ciccodicola A
Oncotarget; 2015 May; 6(13):11242-51. PubMed ID: 25803323
[TBL] [Abstract][Full Text] [Related]
3. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Characterization of Mitochondrial Genome in Papillary Thyroid Cancer.
Su X; Wang W; Ruan G; Liang M; Zheng J; Chen Y; Wu H; Fahey TJ; Guan M; Teng L
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735863
[TBL] [Abstract][Full Text] [Related]
5. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
6. Genomic copy number analysis of Chernobyl papillary thyroid carcinoma in the Ukrainian-American Cohort.
Selmansberger M; Braselmann H; Hess J; Bogdanova T; Abend M; Tronko M; Brenner A; Zitzelsberger H; Unger K
Carcinogenesis; 2015 Nov; 36(11):1381-7. PubMed ID: 26320103
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
Yoo SK; Lee S; Kim SJ; Jee HG; Kim BA; Cho H; Song YS; Cho SW; Won JK; Shin JY; Park do J; Kim JI; Lee KE; Park YJ; Seo JS
PLoS Genet; 2016 Aug; 12(8):e1006239. PubMed ID: 27494611
[TBL] [Abstract][Full Text] [Related]
8. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract][Full Text] [Related]
9. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.
Nakazawa T; Kondo T; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Kubota T; Katoh R
Cancer Med; 2015 Aug; 4(8):1272-80. PubMed ID: 25882744
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
11. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
12. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
13. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
14. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes.
Celestino R; Sigstad E; Løvf M; Thomassen GO; Grøholt KK; Jørgensen LH; Berner A; Castro P; Lothe RA; Bjøro T; Sobrinho-Simões M; Soares P; Skotheim RI
Genes Chromosomes Cancer; 2012 Dec; 51(12):1154-64. PubMed ID: 22961909
[TBL] [Abstract][Full Text] [Related]
15. Somatic amplifications and deletions in genome of papillary thyroid carcinomas.
Passon N; Bregant E; Sponziello M; Dima M; Rosignolo F; Durante C; Celano M; Russo D; Filetti S; Damante G
Endocrine; 2015 Nov; 50(2):453-64. PubMed ID: 25863487
[TBL] [Abstract][Full Text] [Related]
16. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma.
Cheng SP; Hsu YC; Liu CL; Liu TP; Chien MN; Wang TY; Lee JJ
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S619-26. PubMed ID: 24748129
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M; Kloos RT; Lin CF; Travers KJ; Matsuzaki H; Tom EY; Kim SY; Wong MG; Stewart AC; Huang J; Walsh PS; Monroe RJ; Kennedy GC
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):6. PubMed ID: 26818556
[TBL] [Abstract][Full Text] [Related]
18. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.
Torregrossa L; Viola D; Sensi E; Giordano M; Piaggi P; Romei C; Materazzi G; Miccoli P; Elisei R; Basolo F
J Clin Endocrinol Metab; 2016 Nov; 101(11):4413-4420. PubMed ID: 27571181
[TBL] [Abstract][Full Text] [Related]
19. The "next-generation" knowledge of papillary thyroid carcinoma.
Costa V; Esposito R; Pallante P; Ciccodicola A; Fusco A
Cell Cycle; 2015; 14(13):2018-21. PubMed ID: 26030480
[TBL] [Abstract][Full Text] [Related]
20. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
